Streetbeat News

Price Targets

TSVT

Guggenheim analyst Kelsey Goodwin has maintained a 'Buy' rating on 2seventy bio (NASDAQ:TSVT), but lowered the price target from $27 to $26.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:34 pm

MBIO

BTIG analyst Justin Zelin maintains a Buy rating on Mustang Bio (NASDAQ:MBIO) but has lowered the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:33 pm

WELL

RBC Capital analyst Michael Carroll maintains an Outperform rating on Welltower (NYSE:WELL) and raises the price target from $87 to $92.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:31 pm

CNTA

Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:30 pm

OPRX

RBC Capital analyst Sean Dodge has maintained an 'Outperform' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $18 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:29 pm

DCTH

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Delcath Systems (NASDAQ:DCTH) and raises the price target from $17 to $18.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:28 pm

VTSI

Roth MKM analyst Richard Baldry maintains a 'Buy' rating on VirTra (NASDAQ:VTSI) and raises the price target from $13 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:28 pm

VVI

B. Riley Securities analyst Bryan Maher maintains a Buy rating on Viad (NYSE:VVI) and raises the price target from $13 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:26 pm

CSSE

Chicken Soup For The Soul Entertainment (CSSE) reported worse-than-expected Q2 revenue results, leading to a drop in its share price. Multiple firms also downgraded the stock and lowered their price targets.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:21 pm

VIRX

SVB Securities analyst Andrew Berens has maintained an 'Outperform' rating on Viracta Therapeutics (NASDAQ:VIRX), but lowered the price target from $10 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:17 pm